Melanoma Dispatch
Follow
Find tag "TVEC"
1.8K views | +7 today
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

Engineered Virus Shrinks Melanoma Tumors in Phase III Trial

Engineered Virus Shrinks Melanoma Tumors in Phase III Trial | Melanoma Dispatch | Scoop.it

Researchers report that a modified cold sore virus may help deliver longer lasting shrinkage of melanoma tumors. Called talimogene laherparepvec (T-VEC), the engineered virus kills cancer cells directly and boosts the immune response against them by tagging their surfaces with a protein called granulocyte macrophage colony-stimulating factor (GM-CSF). T-VEC outperformed GM-CSF (administered directly) in a phase III trial of 436 people with melanomas that had spread—tumors shrank more often (26% vs 6%) and were more likely to stay shrunk for at least 6 months (16% vs 2%). The researchers caution that while promising, T-VEC is unlikely to be a stand-alone treatment and suggest that this virus might ultimately be combined with another immunotherapy such as ipilimumab.

Cancer Commons's insight:

ASCO Daily News│Jun 3, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Injections that Boost the Immune System Help Shrink Melanomas

Injections that Boost the Immune System Help Shrink Melanomas | Melanoma Dispatch | Scoop.it

A phase III trial suggests that a virus-based treatment could help control melanomas that have spread, according to the pharmaceutical firm Amgen. The treatment, called talimogene laherparepvec, or TVEC, involves injecting tumors with a modified cold sore virus. The modifications make the virus grow in cancer cells, but not in normal cells, and make the cancer cells produce a protein called GM-CSF that stimulates the immune system. More than 250 people in the trial received TVEC injections every two weeks and tumors shrank in about 40 (16%) of those who were treated.

Cancer Commons's insight:

The New York Times │ Mar 19 2013

more...
No comment yet.